Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INCB123667

Small molecule · Inhibitor of cyclin-dependent kinase 2 (CDK2) · developed by Incyte

Phase 3 Most advanced trial
INCY Developer
1 Registered trials

What is INCB123667?

INCB123667 is an orally bioavailable small-molecule inhibitor of cyclin-dependent kinase 2 (CDK2). It binds and inhibits CDK2 activity, blocking retinoblastoma protein phosphorylation and the G1/S transition, which leads to cell cycle arrest. It is being studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
cyclin-dependent kinase 2 (CDK2), cyclin E1 (CCNE1) (binding partner it blocks)
Mechanism
Inhibitor of cyclin-dependent kinase 2 (CDK2)
Pathways
Rb phosphorylation, G1/S cell cycle transition, E2F target gene expression, apoptosis
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07214779 Phase 3 Ovarian Cancer Active not recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Other drugs acting on CDK2

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind INCB123667

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.